胃癌围术期免疫营养治疗进展

doi:10.16689/j.cnki.cn11-9349/r.2020.04.021

PDF(599 KB)

肿瘤代谢与营养电子杂志 ›› 2020, Vol. 7 ›› Issue (4) : 484-489. DOI: 10.16689/j.cnki.cn11-9349/r.2020.04.021

综述

胃癌围术期免疫营养治疗进展

王淼舟1，柳仪1，赵君慧1 柴海萍，1，路娜1，张弢2

作者信息 +

Progress of perioperative immunonutrition therapy for gastric cancer

Wang Miaozhou1, Liu Yi1, Zhao Junhui1, Chai Haipin1, Lu Na1, Zhang Tao2

Author information +

文章历史 +

摘要

免疫是保证人体健康的一种生理功能。目前，人类对其认识和发展共经历了4个阶段（经验免疫学、科学免疫学、现代免疫学、应用免疫学）。其中，在应用免疫学阶段中，衍生出很多分支，例如：免疫治疗、免疫预防及免疫营养等。随着免疫治疗在恶性肿瘤中的崭露头角，不仅证明了其在恶性肿瘤治疗中的可行性和重要性，而且使得人们将该思路拓展到解决肿瘤患者营养不良的问题上。这种通过调节免疫治疗营养不良的方法被称为“免疫营养治疗”，并在近几年临床实践中有了较快速的发展。其中，胃癌作为营养不良发生率最高的癌种，免疫营养治疗在胃癌中的发展备受关注。人们希望通过这种治疗方式降低围术期的不良临床结局、延长患者的总生存时间，此外还迫切希望其可改善患者的生活质量。本文对胃癌患者易发生营养不良的机制、免疫营养维持肠道屏障的作用、常见的免疫营养素在胃癌围术期患者的应用、机制、疗效等进行综述，为胃癌患者围术期的免疫营养治疗提供临床参考。

Abstract

Immunity is a physiological function to ensure human health. At present, human beings have experienced four stages in their understanding and development (empirical immunology, scientific immunology, modern immunology, applied immunology). Among them, in the application of immunology stage, derived a lot of branches, such as: immunotherapy, immune prevention and immune nutrition. With the emergence of immunotherapy in malignant tumors, it not only proves its feasibility and importance in the treatment of malignant tumors, but also makes people extend this idea to solve the problem of malnutrition in tumor patients. This method of regulating immunotherapy for malnutrition is called “immunonutrition therapy” and has been developed rapidly in clinical practice in recent years. Among them, gastric cancer has the highest incidence of malnutrition, and the development of immunonutrition therapy in gastric cancer has attracted much attention. It is hoped that this treatment can reduce perioperative adverse clinical outcomes, prolong patients overall survival, and improve patients quality of life. In this paper, the mechanism of malnutrition in patients with gastric cancer, the role of immune nutrition in maintaining intestinal barrier, and the application, mechanism and efficacy of common immunonutrients in patients with gastric cancer during perioperative period were reviewed, so as to provide clinical reference for the treatment of immune nutrition in patients with gastric cancer during perioperative period.

导出引用

王淼舟，柳仪，赵君慧柴海萍，路娜，张弢. 胃癌围术期免疫营养治疗进展[J]. 肿瘤代谢与营养电子杂志. 2020, 7(4): 484-489 https://doi.org/10.16689/j.cnki.cn11-9349/r.2020.04.021

Wang Miaozhou, Liu Yi, Zhao Junhui, Chai Haipin, Lu Na, Zhang Tao. Progress of perioperative immunonutrition therapy for gastric cancer[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2020, 7(4): 484-489 https://doi.org/10.16689/j.cnki.cn11-9349/r.2020.04.021

参考文献

1.VON MEYENFELDT M F, MEIJERINK W J, ROUFLART M M, et al. Perioperative nutritional support: a randomised clinical trial［J］. Clin Nutr, 1992, 11(4):180-186.
2.ARENDS J, BACHMANN P, BARACOS V, et al. ESPEN guidelines on nutrition in cancer patients［J］. Clin Nutr, 2017, 36(1):11-48.
3.ARENDS J, BARACOS V, Bertz H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr, 2017, 36:1187-1196.
4.吴蓓雯.恶性肿瘤患者营养不良诊断与治疗策略的研究进展［J］.上海护理, 2017, 17(2):5-9.
5.PLANAS M, LVARZ-HHERNANDEZ J, LEON-SANZ M, et al. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES study［J］. Support Care Cancer, 2016, 24(1):429-431.
6.SAGAR R C, KUMAR K V V, RAMACHANDRA CEERENDRA, et al. Perioperative artificial enteral nutrition in malnourished esophageal and stomach cancer patients and its impact on postoperative complications［J］. Indian J Surg Oncol, 2019, 10(3):460-464.
7.ZHU M W, WEI J M, CHEN W, et al. Dynamic investigation of nutritional risk in patients with malignant tumor during hospitalization［J］. Zhonghua Yi Xue Za Zhi, 2018, 98:1093-1098.
8.NEUMAYER L A, SMOUT R J, Horn H G, et al. Early and sufficient feeding reduces length of stay and charges in surgical patients［J］. Surg Res, 2001, 95(1):73-77.
9.林泽晨.胃癌围手术期肠内营养支持治疗的研究进展［J］. 浙江医学, 2019, 41(13):1452-1455.
10.FURST P, POGAN K, STEHLE P. Glutamine dipeptides in clinical nutrition［J］. Nutrition, 1997, 13(7-8):731-737.
11. BOZZETTI F, GAVAZZI C, MICELI R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial［J］. Jepen J Parenter Enteral Nutr, 2000, 24(1):7-14.
12.CEDERHOLM T, BOSAEUS I, BARAZZONI R, et al. Diagnostic criteria for malnutrition - An ESPEN Consensus Statement［J］. Clin Nutr, 2015, 34(3):335-340.
13.SCHATTNER M. Enteral nutritional support of the patient with cancer: route and role［J］. Clin Gastroenterol, 2003, 36(4):297-302.
14.WARBURG O, WIND F, NEGELEIN E. THE METABOLISM OF TUMORS IN THE BODY［J］. Gen Physiol, 1927, 8(6):519-530.
15.师建国, 王瑞安.Warburg效应:肿瘤的因果治疗的契机［J］. 现代肿瘤医学, 2014, 22(6):1459-1461.
16.THOMPSON, CB. Rethinking the regulation of cellular metabolism［J］. Cold Spring Harb Symp Quant Biol, 2011, 76:23-29.
17.PLAS DR, THOMPSON CB.Akt-dependent transformation:there is more to growth than just surviving［J］. Oncogene, 2005, 24(50):7435-7442.
18. ZHOU L, LI S, LIU L, et al. Recombinant methioninase regulates PI3K/Akt/Glut-1 pathway and inhibits aerobic glycolysis to promote apoptosis of gastric cancer cells［J］. Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40:27-33.
19.TRONCONE E FUGAZZA A, CAPPELLO A, et al. Malignant gastric outlet obstruction: Which is the best therapeutic option?［J］. World J Gastroenterol, 2020, 26:1847-1860.
20.FUKAHORI M, SHIBATA M, HAMAUCHI SATOSHI, et al. A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients［J］. Support Care In Cancer, 2020.
21.李文琪, 耿敬姝.免疫检查点抑制剂治疗中胃肠道毒副反应的管理［J］. 现代肿瘤医学, 2019, 27(17):3157-3160.
22.TREMEL H, KIENLE B, WEILEMANN L S, et al. Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal function in the critically ill［J］. Gastroenterology, 1994, 107(6):1595-1601.
23.黄志寅, 唐承薇.肠道微生态与肠黏膜免疫［J］. 中华内科杂志, 2015, 54(5):405-407.
24.REN Z, GUO C, YU S, et al. Progress in mycotoxins affecting intestinal mucosal barrier function［J］. Int J Mol Sci, 2019, 20(11):1-14.
25.CAPALDO C T, FARKAS A E, NUSRAT A. Epithelial adhesive junctions［J］. F1000Prime Rep, 2014, 6(1)
26.陆君阳. 免疫营养素及肠道菌群对结直肠癌治疗的影响机制研究［D］. 北京协和医学院, 2018.
27.冯燕海, 王凤君.紧密连接蛋白Claudin-2研究进展［J］.重庆医学, 2018, 47(5):697-699.
28.LI K, XU Y, HU Y, et al. Effect of enteral immunonutrition on immune, inflammatory markers and nutritional status in gastric cancer patients undergoing gastrectomy: a randomized double-blinded controlled trial［J］. Invest Surg, 2019, 27(4):1-10.
29.刘莉, 王庆兰, 郑永法.免疫营养在消化道肿瘤治疗中的研究现状与进展［J］.中国医药导报, 2019, 16(4):59-62.
30.ADIAMAH A, SKOREPA P, WEIMANN A, et al. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis［J］. Ann Surg, 2019, 270(2):247-256.
31.GIGER-PABST U, LANGE J, MAAURER C, et al. Short-term preoperative supplementation of an immunoenriched diet does not improve clinical outcome in well-nourished patients undergoing abdominal cancer surgery［J］. Nutrition, 2013, 29(5):724-729.
32.SAGAR RC, KUAMR KVV, RAMACHANDRA C, et al. Perioperative artificial enteral nutrition in malnourished esophageal and stomach cancer patients and its impact on postoperative complications［J］. Indian J Surg Oncol, 2019, 10(3):460-464.
33.ADIAMAH A, SKOREPA P, WEIMANN A, et al. The impact of preorative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis［J］. Ann Surg, 2019, 270(2):247-256.
34.刘刚, 周建平, 董明.谷氨酰胺临床研究进展［J］. 中国实用外科杂志, 2018, 38(9):1081-1083,1085.
35.CONG M, SONG C, ZOU B, et al. Impact of glutamine, eicosapntemacnioc acid, branched-chain amino acid supplements on nutritional status and treatment compliance of esophageal cancer patients on concurrent chemoradiotherapy and gastric cancer patients on chemotherapy［J］. Zhonghua Yi Xue Za Zhi, 2015, 95(10):766-769.
36.PENG YL, GONG QF, WAND ZQ.The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients［J］. Chinese Journal Of Cancer, 2006, 25:1044-1047.
37.杨梦媛, 黄坤, 于久飞.谷氨酰胺预防胃癌及结直肠癌化疗相关性腹泻的Meta分析［J］. 中外医学研究, 2018, 16(21):1-4.
38.陶元生.谷氨酰胺肠内营养对老年消化道肿瘤患者术后营养状况及免疫功能的影响［J］.海南医学院学报, 2017, 23(18):2554-2557,2561.
39.YOSHIDA S, KAIBARA A, ISHIBASHI N, et al. Glutamine supplementation in cancer patients［J］. Nutrition, 2001, 17(9):766-768.
40.刘玉迪, 崔久嵬.肿瘤免疫营养治疗［J］. 肿瘤代谢与营养电子杂志, 2015, 2(4):19-24.
41.邓文英, 李宁, 夏欣欣, 等.肿瘤免疫营养现状及进展［J］. 肿瘤学杂志, 2014, 20(8):619-624.
42.陈欢, 郭卫东.ω-3多不饱和脂肪酸相关肠内营养对恶性肿瘤患者营养状态的影响及评估［J］. 世界最新医学信息文摘, 2017, 17(99):46-47.
43.FEIJO PM, RODRIGUES VD, VIANA MS, et al. Effects of ω-3 supplementation on the nutritional status, immune, and inflammatory profiles of gastric cancer patients: A randomized controlled trial［J］. Nutrition, 2019, 61:125-131.
44.李世伟, 杨守梅, 李苏宜.ω-3多不饱和脂肪酸对改善肿瘤病人临床结局的研究进展［J］. 肠外与肠内营养, 2014, 21(5):313-316.
45.滕向龙, 郭景泉, 邹武军.ω-3多不饱和脂肪酸对结直肠癌根治术患者的炎症、营养、免疫功能及预后的影响机制研究［J］. 中国现代医生, 2016, 54(29):13-16.
46.黄龙华, 程芙蓉, 黄艳.肠内营养对胃恶性肿瘤患者术后免疫功能和肠功能的影响［J］. 现代肿瘤医学, 2016, 24(13):2119-2122.
47.FABIAN CJ, KINLER BF, HURSTING SD. omega-3 fatty acids for breast cancer prevention and survivorship［J］. Breast Cancer Res, 2015, 17(1):62.
48.WEI Z, WANG W, CHEN J, et al. A prospective, randomized, controlled study of ω-3 fish oil fat emulsion-based parenteral nutrition for patients following surgical resection of gastric tumors［J］. Nutr I, 2014, 13(1):1-6.
49.雷凯, 祁亚斌.维生素D与结直肠癌的相关性研究进展［J］. 现代医药卫生, 2019, 35(11):1668-1670.
50.VEERALAKSHMANAN P, THAM JC, WRIGHT A, et al. Nutritional deficiency post esophageal and gastric cancer surgery: A quality improvement study［J］. Ann Med Surg (Lond), 2020, 56:19-22.
51.DU J, WEI X, CHEN Y, et al. Microbiota-dependent induction of colonic cyp27b1 is associated with colonic inflammation: implications of locally produced 1, 25-dihydroxyvitamin D3 in inflammatory regulation in the colon［J］. Endocrinology, 2017, 158(11):4064-4075.
52.DU J, CHEN Y, SHI Y, et al. 1, 25-dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway［J］. Inflamm Bowel Dis, 2015, 21(11):2495-2506.
53.WANG Z, YANG H, JIN M, et al. Effects of vitamin D receptor on mucosal barrier proteins in colon cells under hypoxic environment［J］. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2019, 41(4):506-511.
54.HO J, CHAN H, LIANG Y, et al. Cathelicidin preserves intestinal barrier function in polymicrobial sepsis［J］. Crit Care, 2020, 24(1):47.
55.李靓雯, 杨光.维生素D调节肠道炎症反应的研究进展［J］. 医学综述, 2019, 25(7):1272-1276.
56.KONYA V, CZARNEWSKI P, FOEKEL M, et al. Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells［J］. Allergy Clin Immunol, 2018, 141(1):297-292.
57.BARBALHO SM, GOULART RA, GASPARINI R G. Associations between inflammatory bowel diseases and vitamin D［J］. Crit Rev Food Sci Nutr, 2019, 59(8):1347-1356.
58. TIAN Y, NICHOLS R G, CAI J, et al. Vitamin A deficiency in mice alters host and gut microbial metabolism leading to altered energy homeostasis［J］. Nutr Biochem, 2018, 54:28-34.
59.CANTORNA MT, SNYDER L, ARORA J. Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis［J］. Crit Rev Biochem Mol Biol,2019, 54(2):184-192.